Developer docs
API playgroundTry for free, no card

Search company profiles

Precede Biosciences

Full company profile

uuid0000pxc

Namestring
Precede Biosciences
Legal namestring
Precede Biosciences, Inc.
Websiteurl
precede.bio
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Precede Biosciences is a privately held Boston-based biotechnology company that has built a first-in-class liquid biopsy platform for profiling disease-defining transcriptional biology from a 1mL plasma sample. The platform profiles circulating chromatin and the DNA methylome across approximately 20,000 gene promoters, 1 million gene enhancers, and 50,000 CpG islands, then applies proprietary machine-learning classifiers to infer gene expression, pathway activity, and cell states genome-wide. The company was co-founded as a spinout from Dana-Farber Cancer Institute through 5AM Ventures' 4:59 Initiative, with scientific co-founders Sylvan Baca, Toni Choueiri, and Matthew Freedman.

The company delivers this capability through two products: Precede Bio Insight, a Research Use Only (RUO) product offering genome-wide quantitative profiling for biopharmaceutical R&D and academic research, and Precede Bio Dx, which adapts the same platform for clinical-trial patient selection based on target expression, pathway activity, and cell states. Validated use cases include HER2 (AUC 0.97), ER (AUC 0.90), MET (AUC 0.97 in osimertinib-progressing NSCLC), and PSMA classifiers correlated with PSMA-PET imaging, across 15 cancers. The company serves biopharmaceutical developers of next-generation precision medicines (ADCs, radioligands, immune-conjugates, next-generation endocrine therapies), academic and translational research institutions (Dana-Farber, Fred Hutchinson, Emory, Duke, OHSU), and, prospectively, healthcare providers through a future clinical Dx channel.

The business model is a direct, enterprise-field-sales motion into biopharma R&D, structured as research collaborations and RUO service agreements, with a conference-led demand-generation strategy (AACR, ASCO, ESMO, SABCS, ECTRIMS). The company is venture-backed, having raised approximately $83.5M to date ($57M Series A in October 2023 and $63.5M Series B plus a $20M credit facility in January 2026) at a $140.5M post-money valuation, from a syndicate that mixes dedicated life-sciences investors (5AM Ventures, Lilly Asia Ventures, Illumina Ventures, Osage University Partners) with strategic biopharma and channel investors (Bristol Myers Squibb, Labcorp Venture Fund, UPMC Enterprises, Mirae Asset Capital Life Science, Alexandria Venture Investments, Qatar Investment Authority, Binney Street Capital of Dana-Farber). Pricing is not publicly disclosed, and there is no reseller or distributor network.

Short descriptiontext

Precede Biosciences is a Boston-based liquid biopsy company that profiles circulating chromatin and DNA methylome from 1mL of plasma to infer gene expression, pathway activity, and cell states, serving biopharmaceutical developers of next-generation precision cancer therapies and academic researchers through its Precede Bio Insight RUO platform and Precede Bio Dx clinical-trial product.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
liquid biopsy diagnostics, epigenomic profiling, precision oncology platform, circulating chromatin analysis, DNA methylome sequencing
Industry4 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Cancer Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Platform Services for Drug Developers (Research Use Only)
TypeSubscription Recurring
Description

Precede Bio's platform is made available to biopharmaceutical drug developers and academic researchers as a Research Use Only (RUO) product. This is the primary revenue-generating model where the company provides genome-wide liquid biopsy profiling services to support drug development, patient selection, and biomarker discovery.

precede.bio
2Clinical Diagnostic Tests
TypeLicensing Royalties
Description

Development of blood-based clinical tests (Precede Bio Insight™ and Precede Bio Dx™) for use in clinical practice to guide precision cancer treatment decisions, replacing or supplementing invasive tissue-based diagnostics.

precede.bio
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Precede Bio Insight
Description

First-of-its-kind liquid biopsy product enabling genome-wide inference of gene expression, pathway activity, and cell states from just 1mL of plasma

precede.bio
+1 more record
Core offering1 text field

Precede Biosciences operates a first-in-class comprehensive epigenomic liquid biopsy platform that profiles circulating chromatin and the DNA methylome from just 1mL of plasma, delivering genome-wide inference of gene expression, pathway activity, and cell states. The company delivers two commercial products on this platform: Precede Bio Insight™ (a Research Use Only product for biopharma and academic research collaborations) and Precede Bio Dx™ (a clinical trials product enabling non-invasive patient selection based on target expression, pathway activity, and cell states).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • HER2 classifier AUC of 0.97 for HER2 3+ vs HER2 0 in metastatic breast cancer patients with detectable ctDNA
+5 more records
Product overview1 text field

Precede Biosciences offers a unified liquid biopsy platform with two distinct products: Precede Bio Insight™ for research-use genome-wide functional profiling and Precede Bio Dx™ for clinical trial applications. Both products leverage the same core platform technology that analyzes circulating chromatin and DNA methylome from 1mL of plasma to provide genome-wide transcriptional biology insights, enabling researchers and clinicians to understand disease biology in real time for patient selection, therapeutic development, and treatment decisions.

Product and service3 records
1Precede Bio Insight™
CategoryLiquid Biopsy Diagnostics / RUO Platform
Description

A first-of-its-kind genome-wide liquid biopsy product that enables genome-wide inference of gene expression, pathway activity, and cell states from just 1 mL of plasma. Powered by comprehensive epigenomic profiling of cell-free DNA and advanced machine learning, Insight generates quantitative measures of tumor and immune transcriptional biology including target expression, pathway activity, and cell states. Available for R&D collaborations with biopharmaceutical and academic research partners as a Research Use Only (RUO) product.

2Precede Bio Dx™
CategoryClinical Trial Diagnostics
Description

Clinical trials product that brings Precede's comprehensive epigenomic profiling platform into clinical trial settings, enabling non-invasive patient selection based on target expression, pathway activity, and cell states. Designed to support drug developers in identifying biology associated with response and resistance, identifying novel targets, informing patient selection for clinical trials, and guiding combination and sequencing strategies for precision medicines.

3Precede Liquid Biopsy Platform
CategoryLiquid Biopsy Platform Technology
Description

A first-in-class liquid biopsy platform that profiles circulating chromatin and DNA methylome from just 1mL of plasma. The platform provides genome-wide resolution into ~20K gene promoters, ~1M gene enhancers, and ~50K CpG islands, enabling dynamic analysis of gene and pathway activation in diseased tissues from a simple blood draw. Available as Research Use Only (RUO) to drug developers and academic researchers.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-05-31
Description

ASCO 2026 data included studies on MET activation in EGFR-mutated advanced NSCLC patients progressing on osimertinib (AstraZeneca's EGFR inhibitor), demonstrating the platform's ability to inform patient selection and resistance monitoring for targeted therapy combinations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Dana-Farber Cancer Institute is a co-founder institution and active research collaborator. Co-founders Sylvan Baca, MD, PhD, Toni Choueiri, MD, and Matthew Freedman, MD are faculty members. Multiple joint studies presented at AACR 2026, including characterization of functional ER dependence and neuroendocrine prostate cancer profiling.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Fred Hutchinson Cancer Center collaborated on AACR 2026 studies demonstrating the platform's ability to predict therapeutic response and reveal resistance mechanisms in breast and prostate cancer.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Genentech collaborated on AACR 2026 data demonstrating that a liquid biopsy assay of estrogen receptor activity predicts response to giredestrant in ER+/HER2- advanced breast cancer, supporting development of next-generation SERD therapies.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Emory University School of Medicine collaborated on AACR 2026 studies including plasma-based comprehensive epigenomic profiling enabling multiplexed prediction of target gene expression and detection of resistance mechanisms in neuroendocrine prostate cancer. Dr. Jacob E. Berchuck led related PSMA studies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Established liquid biopsy company offering comprehensive genomic profiling (Guardant360) and MRD (Guardant Reveal) tests for oncology. Most directly comparable to Precede in the liquid biopsy precision-oncology category, though Guardant focuses on ctDNA mutation/single-molecule-level detection rather than epigenomic profiling.

TypeBroad incumbent
Description

Roche-owned leader in comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx) used for oncology patient selection and biopharma trial enrollment. Direct category competitor for cancer liquid biopsy and the platform against which Precede Bio Dx would most likely be benchmarked in clinical trials.

TypeDirect peer
Description

Molecular diagnostics company with Signatera (tumor-informed MRD) and other oncology blood-based tests. Direct peer in the liquid biopsy / oncology patient-selection space, with established biopharma and clinical channels Precede is targeting.

TypeBroad incumbent
Description

Diversified molecular diagnostics leader with Cologuard and the acquired Thrive/CancerSEEK programs. Competitor in oncology liquid biopsy and biomarker discovery with far larger commercial infrastructure and scale Precede would need to challenge.

TypeDirect peer
Description

Genomics-based liquid biopsy player (NeXT Personal liquid biopsy assay) focused on ultrasensitive MRD and tumor profiling for biopharma trial patient selection. Closest peer to Precede by platform category and target customer (biopharma), though Personalis uses genomic rather than epigenomic readouts.

6Tempus AI
TypeBroad incumbent
Description

AI-enabled precision medicine company combining broad genomic profiling with multimodal data and biopharma trial services. Competes for the same biopharma patient-selection and biomarker-discovery budget as Precede Bio Insight.

TypeDirect peer
Description

Specialized oncology reference lab offering both tissue and liquid biopsy comprehensive genomic profiling for solid tumor and MRD use cases. Comparable in oncology diagnostic service delivery and biopharma partnership orientation.

TypeEmerging player
Description

Molecular profiling company offering MI Profile (tissue) and MI Cancer Seek (blood) comprehensive assays across DNA, RNA, and protein for oncology patient selection. Comparable in offering multi-omic / comprehensive profiling from blood, with overlapping biopharma customers.

TypeRegional player
Description

China-based oncology liquid biopsy and precision diagnostics company with US operations. Comparable in offering comprehensive NGS liquid biopsy for cancer patient selection, primarily a regional rather than US-headquartered competitor.

TypeEmerging player
Description

ImmunoSEQ and clonoSEQ diagnostics apply sequencing-based blood profiling to characterize immune and minimal residual disease biology. Adjacent in the blood-based oncology/biomarker profiling category, particularly for immune-cell readouts that complement Precede's chromatin/methylation assays.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Precede Biosciences

Cancer Diagnosticsprecede.bio

Precede Biosciences is a Boston-based liquid biopsy company that profiles circulating chromatin and DNA methylome from 1mL of plasma to infer gene expression, pathway activity, and cell states, serving biopharmaceutical developers of next-generation precision cancer therapies and academic researchers through its Precede Bio Insight RUO platform and Precede Bio Dx clinical-trial product.

What Precede Biosciences does

Precede Biosciences is a privately held Boston-based biotechnology company that has built a first-in-class liquid biopsy platform for profiling disease-defining transcriptional biology from a 1mL plasma sample. The platform profiles circulating chromatin and the DNA methylome across approximately 20,000 gene promoters, 1 million gene enhancers, and 50,000 CpG islands, then applies proprietary machine-learning classifiers to infer gene expression, pathway activity, and cell states genome-wide. The company was co-founded as a spinout from Dana-Farber Cancer Institute through 5AM Ventures' 4:59 Initiative, with scientific co-founders Sylvan Baca, Toni Choueiri, and Matthew Freedman.

The company delivers this capability through two products: Precede Bio Insight, a Research Use Only (RUO) product offering genome-wide quantitative profiling for biopharmaceutical R&D and academic research, and Precede Bio Dx, which adapts the same platform for clinical-trial patient selection based on target expression, pathway activity, and cell states. Validated use cases include HER2 (AUC 0.97), ER (AUC 0.90), MET (AUC 0.97 in osimertinib-progressing NSCLC), and PSMA classifiers correlated with PSMA-PET imaging, across 15 cancers. The company serves biopharmaceutical developers of next-generation precision medicines (ADCs, radioligands, immune-conjugates, next-generation endocrine therapies), academic and translational research institutions (Dana-Farber, Fred Hutchinson, Emory, Duke, OHSU), and, prospectively, healthcare providers through a future clinical Dx channel.

The business model is a direct, enterprise-field-sales motion into biopharma R&D, structured as research collaborations and RUO service agreements, with a conference-led demand-generation strategy (AACR, ASCO, ESMO, SABCS, ECTRIMS). The company is venture-backed, having raised approximately $83.5M to date ($57M Series A in October 2023 and $63.5M Series B plus a $20M credit facility in January 2026) at a $140.5M post-money valuation, from a syndicate that mixes dedicated life-sciences investors (5AM Ventures, Lilly Asia Ventures, Illumina Ventures, Osage University Partners) with strategic biopharma and channel investors (Bristol Myers Squibb, Labcorp Venture Fund, UPMC Enterprises, Mirae Asset Capital Life Science, Alexandria Venture Investments, Qatar Investment Authority, Binney Street Capital of Dana-Farber). Pricing is not publicly disclosed, and there is no reseller or distributor network.

Precede Biosciences firmographics

Firmographics
Name
Precede Biosciences
Legal name
Precede Biosciences, Inc.
Website
https://precede.bio
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
51–100 employees
Short description
Precede Biosciences is a Boston-based liquid biopsy company that profiles circulating chromatin and DNA methylome from 1mL of plasma to infer gene expression, pathway activity, and cell states, serving biopharmaceutical developers of next-generation precision cancer therapies and academic researchers through its Precede Bio Insight RUO platform and Precede Bio Dx clinical-trial product.
Ownership category
akta.pro rank

Precede Biosciences industry classification

Industry
Product category
Cancer Diagnostics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Liquid biopsy diagnostics
  • Epigenomic profiling
  • Precision oncology platform
  • Circulating chromatin analysis
  • DNA methylome sequencing

Where Precede Biosciences is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Precede Biosciences business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Platform Services for Drug Developers (Research Use Only): Precede Bio's platform is made available to biopharmaceutical drug developers and academic researchers as a Research Use Only (RUO) product. This is the primary revenue-generating model where the company provides genome-wide liquid biopsy profiling services to support drug development, patient selection, and biomarker discovery.
  2. Clinical Diagnostic Tests: Development of blood-based clinical tests (Precede Bio Insight™ and Precede Bio Dx™) for use in clinical practice to guide precision cancer treatment decisions, replacing or supplementing invasive tissue-based diagnostics.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Precede Biosciences product offering

Product offering

Core offering

Precede Biosciences operates a first-in-class comprehensive epigenomic liquid biopsy platform that profiles circulating chromatin and the DNA methylome from just 1mL of plasma, delivering genome-wide inference of gene expression, pathway activity, and cell states. The company delivers two commercial products on this platform: Precede Bio Insight™ (a Research Use Only product for biopharma and academic research collaborations) and Precede Bio Dx™ (a clinical trials product enabling non-invasive patient selection based on target expression, pathway activity, and cell states).

Product overview

Precede Biosciences offers a unified liquid biopsy platform with two distinct products: Precede Bio Insight™ for research-use genome-wide functional profiling and Precede Bio Dx™ for clinical trial applications. Both products leverage the same core platform technology that analyzes circulating chromatin and DNA methylome from 1mL of plasma to provide genome-wide transcriptional biology insights, enabling researchers and clinicians to understand disease biology in real time for patient selection, therapeutic development, and treatment decisions.

Differentiator

Problem solved

Functional benefit

Brands

  • Precede Bio Insight: First-of-its-kind liquid biopsy product enabling genome-wide inference of gene expression, pathway activity, and cell states from just 1mL of plasma
  • Precede Bio Dx

Products and services

  • Precede Bio Insight™ A first-of-its-kind genome-wide liquid biopsy product that enables genome-wide inference of gene expression, pathway activity, and cell states from just 1 mL of plasma. Powered by comprehensive epigenomic profiling of cell-free DNA and advanced machine learning, Insight generates quantitative measures of tumor and immune transcriptional biology including target expression, pathway activity, and cell states. Available for R&D collaborations with biopharmaceutical and academic research partners as a Research Use Only (RUO) product.
  • Precede Bio Dx™ Clinical trials product that brings Precede's comprehensive epigenomic profiling platform into clinical trial settings, enabling non-invasive patient selection based on target expression, pathway activity, and cell states. Designed to support drug developers in identifying biology associated with response and resistance, identifying novel targets, informing patient selection for clinical trials, and guiding combination and sequencing strategies for precision medicines.
  • Precede Liquid Biopsy Platform A first-in-class liquid biopsy platform that profiles circulating chromatin and DNA methylome from just 1mL of plasma. The platform provides genome-wide resolution into ~20K gene promoters, ~1M gene enhancers, and ~50K CpG islands, enabling dynamic analysis of gene and pathway activation in diseased tissues from a simple blood draw. Available as Research Use Only (RUO) to drug developers and academic researchers.

Quantifiable outcome

  • HER2 classifier AUC of 0.97 for HER2 3+ vs HER2 0 in metastatic breast cancer patients with detectable ctDNA
  • +5 more outcomes

Companies that use Precede Biosciences

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Precede Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Precede Biosciences partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered major and core.

  • AstraZenecamajorStrategic or Co-development Partner · 31 May 2026ASCO 2026 data included studies on MET activation in EGFR-mutated advanced NSCLC patients progressing on osimertinib (AstraZeneca's EGFR inhibitor), demonstrating the platform's ability to inform patient selection and resistance monitoring for targeted therapy combinations.
  • Dana-Farber Cancer InstitutecoreStrategic or Co-development Partner · 22 April 2026Dana-Farber Cancer Institute is a co-founder institution and active research collaborator. Co-founders Sylvan Baca, MD, PhD, Toni Choueiri, MD, and Matthew Freedman, MD are faculty members. Multiple joint studies presented at AACR 2026, including characterization of functional ER dependence and neuroendocrine prostate cancer profiling.
  • Fred Hutchinson Cancer CentermajorStrategic or Co-development Partner · 22 April 2026Fred Hutchinson Cancer Center collaborated on AACR 2026 studies demonstrating the platform's ability to predict therapeutic response and reveal resistance mechanisms in breast and prostate cancer.
  • GenentechmajorStrategic or Co-development Partner · 22 April 2026Genentech collaborated on AACR 2026 data demonstrating that a liquid biopsy assay of estrogen receptor activity predicts response to giredestrant in ER+/HER2- advanced breast cancer, supporting development of next-generation SERD therapies.
  • Emory University School of MedicinemajorStrategic or Co-development Partner · 22 April 2026Emory University School of Medicine collaborated on AACR 2026 studies including plasma-based comprehensive epigenomic profiling enabling multiplexed prediction of target gene expression and detection of resistance mechanisms in neuroendocrine prostate cancer. Dr. Jacob E. Berchuck led related PSMA studies.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Precede Biosciences competitors and assessment

Company assessment

Direct peers

  • Guardant Health: Established liquid biopsy company offering comprehensive genomic profiling (Guardant360) and MRD (Guardant Reveal) tests for oncology. Most directly comparable to Precede in the liquid biopsy precision-oncology category, though Guardant focuses on ctDNA mutation/single-molecule-level detection rather than epigenomic profiling.
  • Natera: Molecular diagnostics company with Signatera (tumor-informed MRD) and other oncology blood-based tests. Direct peer in the liquid biopsy / oncology patient-selection space, with established biopharma and clinical channels Precede is targeting.
  • Personalis: Genomics-based liquid biopsy player (NeXT Personal liquid biopsy assay) focused on ultrasensitive MRD and tumor profiling for biopharma trial patient selection. Closest peer to Precede by platform category and target customer (biopharma), though Personalis uses genomic rather than epigenomic readouts.
  • NeoGenomics: Specialized oncology reference lab offering both tissue and liquid biopsy comprehensive genomic profiling for solid tumor and MRD use cases. Comparable in oncology diagnostic service delivery and biopharma partnership orientation.

Broad incumbents

  • Foundation Medicine: Roche-owned leader in comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx) used for oncology patient selection and biopharma trial enrollment. Direct category competitor for cancer liquid biopsy and the platform against which Precede Bio Dx would most likely be benchmarked in clinical trials.
  • Exact Sciences: Diversified molecular diagnostics leader with Cologuard and the acquired Thrive/CancerSEEK programs. Competitor in oncology liquid biopsy and biomarker discovery with far larger commercial infrastructure and scale Precede would need to challenge.
  • Tempus AI: AI-enabled precision medicine company combining broad genomic profiling with multimodal data and biopharma trial services. Competes for the same biopharma patient-selection and biomarker-discovery budget as Precede Bio Insight.

Emerging players

  • Caris Life Sciences: Molecular profiling company offering MI Profile (tissue) and MI Cancer Seek (blood) comprehensive assays across DNA, RNA, and protein for oncology patient selection. Comparable in offering multi-omic / comprehensive profiling from blood, with overlapping biopharma customers.
  • Adaptive Biotechnologies: ImmunoSEQ and clonoSEQ diagnostics apply sequencing-based blood profiling to characterize immune and minimal residual disease biology. Adjacent in the blood-based oncology/biomarker profiling category, particularly for immune-cell readouts that complement Precede's chromatin/methylation assays.

Regional players

  • Burning Rock Biotech: China-based oncology liquid biopsy and precision diagnostics company with US operations. Comparable in offering comprehensive NGS liquid biopsy for cancer patient selection, primarily a regional rather than US-headquartered competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Precede Biosciences social profiles

Digital presence

Precede Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Precede Biosciences leadership team

Management profile

Number of profiles

Profiles14 records

Precede Biosciences funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Precede Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Precede Biosciences

What does Precede Biosciences do?

Precede Biosciences operates a first-in-class comprehensive epigenomic liquid biopsy platform that profiles circulating chromatin and the DNA methylome from just 1mL of plasma, delivering genome-wide inference of gene expression, pathway activity, and cell states. The company delivers two commercial products on this platform: Precede Bio Insight™ (a Research Use Only product for biopharma and academic research collaborations) and Precede Bio Dx™ (a clinical trials product enabling non-invasive patient selection based on target expression, pathway activity, and cell states).

Is Precede Biosciences a public or private company?

Precede Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Precede Biosciences founded?

Precede Biosciences was founded in 2023. It employs 51 to 100 people.

Where is Precede Biosciences based?

Precede Biosciences is headquartered in Boston, United States, in the North America region.

How does Precede Biosciences make money?

Two revenue lines are on record. Platform Services for Drug Developers (Research Use Only) is the primary driver. The others are clinical Diagnostic Tests.

Who are Precede Biosciences's main competitors?

Direct peers on record are Guardant Health, Natera, Personalis and NeoGenomics. Broad incumbents are Foundation Medicine, Exact Sciences and Tempus AI. Emerging players are Caris Life Sciences and Adaptive Biotechnologies. Burning Rock Biotech is listed as a regional player.

Does Precede Biosciences have an API?

No public API is recorded for Precede Biosciences.

What industry is Precede Biosciences in?

Precede Biosciences's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing. Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Financial PostPrecede Biosciences Presents ESMO 2026 Data Revealing Biology Associated with Response and Resistance to PSMA-Directed Radioligand Therapy in Advanced Prostate CancerPrecede Biosciences presented ESMO 2026 data on plasma profiling of 57 metastatic castration-resistant prostate cancer patients treated with 177Lu-PSMA-617. Baseline profiling identified three molecular states, with AR-high/metabolic showing the best outcomes, and PSMA expression declined in 11 of 17 patients at progression. The findings support investigating treatment-sequencing strategies involving alternative PSMA-targeting modalities.FinancialContent Business PagePrecede Biosciences Presents ESMO 2026 Data Revealing Biology Associated with Response and Resistance to PSMA-Directed Radioligand Therapy in Advanced Prostate CancerPrecede Biosciences presented ESMO 2026 data on plasma profiling of 57 metastatic castration-resistant prostate cancer patients treated with 177Lu-PSMA-617. Baseline profiling identified three molecular states, with AR-high/metabolic showing the most favorable trends. At progression, predicted PSMA expression declined in 11 of 17 patients, supporting treatment-sequencing strategies.GlobeNewswirePrecede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight™ to Decode MET-Driven Biology and Resistance in Advanced NSCLCPrecede Biosciences presented new data at the 2026 ASCO Annual Meeting in Chicago demonstrating the capabilities of its Precede Bio Insight™ liquid biopsy platform to decode MET-driven biology and resistance mechanisms in advanced non-small cell lung cancer (NSCLC) using only 1 mL of plasma. The plasma MET test showed high concordance with tissue-based testing (AUC=0.97) in EGFR-mutated NSCLC patients progressing on osimertinib, and identified biological markers associated with therapeutic sensitivity and resistance including MET pathway activity, neuroendocrine lineage plasticity, and ADC target expression.BioSpacePrecede Biosciences Launches Precede Bio Insight™, a Genome-Wide Liquid Biopsy for Functional Tumor Biology at AACR 2026Precede Biosciences launched Precede Bio Insight, a genome-wide liquid biopsy from 1 mL of plasma, at AACR 2026. The product enables quantitative inference of gene expression and pathway activity, with studies showing concordance to tissue measures and prediction of therapeutic response.GlobeNewswirePrecede Biosciences Launches Precede Bio Insight™, a Genome-Wide Liquid Biopsy for Functional Tumor Biology at AACR 2026Precede Biosciences launched Precede Bio Insight, a first-of-its-kind liquid biopsy product enabling genome-wide inference of gene expression, pathway activity, and cell states from just 1 mL of plasma, at the AACR 2026 Annual Meeting. Three supporting studies presented at the conference, conducted in collaboration with Dana-Farber Cancer Institute, Fred Hutchinson Cancer Center, Genentech, and Emory University School of Medicine, demonstrated the assay's ability to predict therapeutic response and reveal resistance mechanisms in breast and prostate cancer. The launch addresses a gap in cancer clinical trials where approximately 300,000 patients are enrolled annually but access to real-time functional tumor biology has been limited.The Manila TimesPrecede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics PlatformPrecede Biosciences announced the close of an $83.5 million financing round, comprising $63.5 million in Series B equity and a $20 million non-dilutive credit facility, to scale its blood-based precision diagnostics platform for next-generation cancer therapies including drug-, radio-, and immune-conjugates. New strategic investors joining the syndicate include Labcorp Venture Fund, UPMC Enterprises, Mirae Asset Capital Life Science, and Alexandria Venture Investments, while existing investors Bristol Myers Squibb, Illumina Ventures, 5AM Ventures, and Lilly Asia Ventures maintained or increased their positions. The company highlighted that over 1,500 next-generation precision medicines are currently in development, creating rapidly growing demand for diagnostic platforms capable of profiling multiple targets and pathways from a single blood draw.American City Business JournalsUPMC Enterprises invests in Precede Biosciences' $83.5M roundBoston-based startup Precede Biosciences, which develops blood-based analysis to guide cancer treatment decisions, closed an $83.5 million financing round with Pittsburgh-based UPMC Enterprises participating as a new investor. The precision medicine company focuses on analyzing blood samples to help inform treatment choices for cancer patients. The funding represents a significant investment in the growing field of precision oncology diagnostics.GlobeNewswirePrecede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung CancerPrecede Biosciences presented new data at the ESMO Congress 2025 in Berlin demonstrating its liquid biopsy platform's ability to resolve gene expression of clinically relevant drug targets such as DLL3, SEZ6, and CEACAM5, and to classify SCLC molecular subtypes from just 1 mL of patient plasma. The platform combines comprehensive epigenomic profiling of circulating tumor DNA with machine learning to infer gene expression non-invasively. The findings highlight potential applications for informing therapeutic decision-making in small cell lung cancer, an aggressive disease accounting for 15% of lung cancers with approximately 12-month median survival for extensive-stage patients.GlobeNewswirePrecede Biosciences Presents ASCO 2025 Data Highlighting the Ability of its Liquid Biopsy Platform to Reveal the Biology Underlying Response and Resistance to ADCs and RadiopharmaceuticalsPrecede Biosciences presented ASCO 2025 data showing its plasma-based epigenomic platform identifies response and resistance pathways in patients treated with sacituzumab govitecan and 177Lu-PSMA-617. The platform's ability to decode transcriptional biology underlies therapeutic outcomes, and the company plans to continue collaborating with drug developers.